机构:[1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China[2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China[3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China[4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China[5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China[6]Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, Guangdong, China
National Key Research and Development Program of China (2018YFC1704200), the Major Basic and
Applied Basic Research Projects of Guangdong Province of China
(2019B030302005), the Key Project of the National Natural Science
Foundation of China (81530102), the Basic and Applied Basic Research
Project of Guangdong Province of China (2018A030313391,
2019A1515110123, 2020A1515010155, 2021A1515012553), and the
“Innovation and Strengthening University Project” Subsidized Project of
Guangdong Pharmaceutical University (2018KTSCX112).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
第一作者:
第一作者机构:[1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China[2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China[3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China[4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China[5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
共同第一作者:
通讯作者:
通讯机构:[1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China[2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China[3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China[4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China[5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China[*1]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China.
推荐引用方式(GB/T 7714):
Wang Lexun,Zhang Dongxing,Zhan Wenjing,et al.Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs[J].BIOMEDICINE & PHARMACOTHERAPY.2022,156:113831.doi:10.1016/j.biopha.2022.113831.
APA:
Wang Lexun,Zhang Dongxing,Zhan Wenjing,Zeng Zhihuan,Yin Jianying...&Guo Jiao.(2022).Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs.BIOMEDICINE & PHARMACOTHERAPY,156,
MLA:
Wang Lexun,et al."Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs".BIOMEDICINE & PHARMACOTHERAPY 156.(2022):113831